Mr. Thomas Looby reports

CONAVI MEDICAL ANNOUNCES JSCAI PUBLICATION DEMONSTRATING THE CLINICAL UTILITY OF HYBRID IVUS OCT IMAGING

Conavi Medical Corp. has published a case report in the Journal of the Society for Cardiovascular Angiography & Interventions (JSCAI) titled "Versatility of Hybrid OCT and IVUS Imaging Enhances Contrast-Sparing Management of Eruptive Calcified Nodules." The publication features Conavi's hybrid intravascular ultrasound (IVUS) and optical coherence tomography (OCT) imaging system in a complex coronary procedure involving a patient with impaired renal function, where managing contrast exposure was an important consideration. The publication follows Conavi's April 20, 2026, announcement that it received United States Food and Drug Administration (FDA) 510(k) clearance for its next-generation hybrid IVUS-OCT imaging system.

"Following our recent FDA clearance, we are focused on advancing the commercial rollout of Conavi's hybrid IVUS-OCT imaging system and building the clinical evidence to support adoption," said Thomas Looby, president and chief executive officer of Conavi Medical. "This JSCAI case report demonstrates the practical value of having IVUS and OCT available through a single hybrid system to assess complex lesions, support treatment planning and help manage contrast use during image-guided PCI."

"Hybrid imaging gave us the ability to use OCT when its higher resolution was most useful, while relying on IVUS-only imaging to reduce contrast exposure during the procedure," said Dr. Megha Prasad, co-author of the publication and interventional cardiologist. "The co-registered view supported complete lesion assessment (obtaining information on calcium, thrombus, vessel size and the final stent result), leveraging the individual benefits of each imaging modality."

"This approach fundamentally changed how we made decisions during the procedure. Rather than being locked into a single imaging modality from the outset, we could select the imaging technique that best served the patient at each stage of the case. That flexibility allowed us to adapt in real time without compromising on patient care."

The case report highlights several practical advantages of Conavi's hybrid IVUS-OCT imaging, including the ability to:

• Use OCT's high-resolution imaging to help visualize thrombus overlying the calcified nodule;
• Use IVUS to delineate the calcium arc and support lesion assessment;
• Toggle between hybrid imaging and IVUS-only pullbacks during the procedure;
• Support stent optimization while limiting contrast exposure in a patient with impaired renal function.

The procedure demonstrated how OCT could be used selectively when high-resolution imaging was needed, while IVUS-only imaging was relied upon during other stages of the intervention to help minimize contrast exposure in a patient with impaired renal function.

The authors noted that diagnosing eruptive calcified nodules can be challenging when using IVUS or OCT alone, due to the individual limitations of each imaging modality, particularly in patients with impaired renal function. The publication concluded that hybrid IVUS-OCT imaging may play an important role in patients with challenging plaque morphology, especially in the setting of chronic kidney disease.

About Conavi Medical Corp.

Conavi Medical is focused on designing, manufacturing and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented hybrid imaging system is the first system to co-register and co-align intravascular ultrasound (IVUS) and optical coherence tomography (OCT) imaging beams to enable simultaneous hybrid imaging of coronary arteries. The hybrid imaging system has 510(k) clearance from the U.S. Food and Drug Administration.

We seek Safe Harbor.